Hercules Capital, Inc. provides senior secured venture growth loans to high-growth, venture capital-backed and institutional-backed companies, with an emphasis on technology and life sciences industries. Its updates commonly address debt and equity commitments, loan fundings, portfolio-company financings, net investment income, net asset value, leverage, available liquidity and recurring cash distributions.
Hercules also reports developments involving credit ratings, annual meeting and proxy matters, executive leadership, and its asset management activity through Hercules Adviser LLC and related Adviser Funds. The company’s common stock trades on the NYSE under HTGC, and its retail notes trade under HCXY.
Hercules Capital (NYSE: HTGC) and its adviser subsidiary’s managed private funds originated more than $4.0 billion in debt and equity commitments year-to-date.
The combined commitments surpassed the previous one-year record of $3.92 billion, marking the first time the platform exceeded $4.0 billion in annual commitments. The milestone follows record commitments for the first three quarters of 2026.
Atea Pharmaceuticals (Nasdaq: AVIR) entered a credit facility with Hercules Capital for up to $200 million to support its antiviral programs. Atea received $65 million at closing; further funding depends on milestones, agreement terms or lender discretion. The facility matures in 60 months, with a 48-month interest-only period that can extend to 60 months upon a specified commercial milestone.
Atea expects existing cash and investments plus the initial borrowing to fund planned operations into mid-2028. It expects results from its second Phase 3 hepatitis C trial, C-FORWARD, in early Q1 2027 and plans a US marketing application for bemnifosbuvir/ruzasvir in mid-2027. Its US launch goal is 2028, if approved; the financing also supports its hepatitis E clinical program.
Hercules Capital (HTGC) reported third-quarter 2026 net investment income of $87.3 million, covering its base cash distribution for the quarter. Net investment income was $0.47 per share, providing 118% coverage. For the year to date through Q3, investment income rose 9.0% year over year to $430.8 million, while net investment income increased 5.4% to $268.4 million.
Year-to-date new debt and equity commitments reached $3.44 billion, up 20.0%, and fundings rose 9.9% to $1.93 billion. Quarter-end available liquidity exceeded $1.0 billion, including adviser funds. Net GAAP leverage was 109.0%, and net regulatory leverage was 94.0%.
Hercules Capital (NYSE: HTGC) declared a third-quarter 2026 cash distribution of $0.47 per share, payable November 17, 2026. The payment comprises a $0.40 base distribution and a $0.07 supplemental distribution. The record date is November 10, 2026.
The board maintains a variable distribution policy targeting quarterly payments that approximate 90% to 100% of taxable quarterly income or potential annual income for a particular year. It may pay supplemental distributions or carry excess taxable income into the next year for future payments.
Hercules Capital (HTGC) announced that Fitch affirmed its investment-grade corporate and unsecured credit rating at BBB-, with a stable outlook. Fitch also affirmed the company’s secured debt rating at BBB. The ratings reflect its first-lien investment focus, credit track record, consistent operating performance and funding flexibility.
Hercules Capital (NYSE: HTGC) will release its third quarter 2026 financial results after market close on October 29, 2026.
A conference call will follow at 2:00 p.m. PT (5:00 p.m. ET), with telephone access and a live webcast. An archived webcast replay will be available through the company's Investor Relations website.
Hercules Capital (NYSE: HTGC) closed an upsized underwritten public offering of $400.0 million in unsecured notes due in October 2029.
The notes pay 6.700% annual interest semiannually and mature October 8, 2029. Hercules expects to use net proceeds to repay outstanding unsecured and/or secured debt, fund investments and support general corporate purposes. Initial ratings were Baa2 from Moody’s and BBB- from Fitch.
Rocket Pharmaceuticals (RCKT) entered a credit facility agreement with Hercules Capital (HTGC) for up to $150 million to support cardiovascular development. Rocket received $35 million at closing and may draw another $35 million during specified periods, subject to agreement terms. Another $30 million depends on a Danon clinical milestone; $50 million requires Hercules’ investment committee approval.
The facility has an initial 30-month interest-only period, a 48-month maturity and milestone-dependent extensions. It also includes warrants to purchase Rocket common stock. Rocket expects its existing resources plus the initial funding to support operations into the third quarter of 2028. Further borrowing could extend its runway into 2029, depending on borrowing conditions, draw timing and amounts, and operating expenditures.
Hercules Capital (NYSE: HTGC) priced an underwritten public offering of $400.0 million in unsecured notes to finance its disclosed funding needs. The notes bear 6.70% annual interest, payable semiannually, and mature on October 8, 2029. Delivery and payment are expected on October 8, 2026, subject to customary closing conditions.
The company expects to use net proceeds to repay outstanding unsecured and/or secured indebtedness under existing financing arrangements, fund investments and support general corporate purposes. Hercules may redeem the notes in whole or in part at its option at par, plus a make-whole premium, if applicable—a payment associated with early redemption.
NorthStar Medical Technologies secured a growth-capital facility of up to $185 million from Hercules Capital (HTGC).
The multi-year facility includes $100 million upfront to support expanded isotope production and clinical and commercial drug manufacturing. NorthStar began commercial-scale production of no-carrier-added actinium-225 in January 2026, and the FDA has since accepted its Drug Master File for the isotope. NorthStar plans to transition to a high-capacity production line later this year. It also expanded its partnership with Convergent to support late-stage clinical studies and commercial demand.